Systemic AA amyloidosis caused by inflammatory hepatocellular adenoma
- Resource Type
- Authors
- Oriol Bestard; Jessica Zucman-Rossi; Julien Calderaro; Dominique Franco; Jean-Charles Nault; Victor Renault; Michel Moutschen; Quentin Bayard; Eric Letouzé; Jean-François Deleuze; Anais Boulai; Elie-Serge Zafrani
- Source
- Dipòsit Digital de la UB
Universidad de Barcelona
New England Journal of Medicine
New England Journal of Medicine, Massachusetts Medical Society, 2018, 379 (12), pp.1178-1180. ⟨10.1056/NEJMc1805673⟩
New England Journal of Medicine, 2018, 379 (12), pp.1178-1180. ⟨10.1056/NEJMc1805673⟩
- Subject
- Serum
Pathology
medicine.medical_specialty
endocrine system diseases
Adenoma
Liver cytology
[SDV]Life Sciences [q-bio]
Lesion
03 medical and health sciences
0302 clinical medicine
Fetge
AA amyloidosis
Gene expression
medicine
ComputingMilieux_MISCELLANEOUS
business.industry
Sèrum
Proteins
General Medicine
Amyloidosis
Hepatocellular adenoma
medicine.disease
digestive system diseases
3. Good health
stomatognathic diseases
Liver
030220 oncology & carcinogenesis
Inflammatory Hepatocellular Adenoma
Amiloïdosi
030211 gastroenterology & hepatology
medicine.symptom
business
Liver pathology
Proteïnes
- Language
- ISSN
- 0028-4793
1533-4406
To the Editor: Amyloid A (AA) systemic amyloidosis is a complication of chronic inflammatory diseases that is caused by the deposition of insoluble aggregates of cleaved N-terminal fragments of serum amyloid A (SAA) protein in tissues and organs throughout the body. Under physiologic conditions, SAA protein is produced by hepatocytes during the acute inflammatory phase in response to various cytokines such as interleukin-6. SAA is also overexpressed by neoplastic hepatocytes in inflammatory hepatocellular adenomas, a specific molecular subtype of benign liver tumors.